Group 1: New IPOs Overview - Three new stocks are available for subscription next week, including Fengbei Biological, Zhongcheng Consulting, and Delijia [2] - Fengbei Biological has an issuance price of 24.49 CNY per share and a P/E ratio of 30.47, significantly lower than the industry average of 64.73 [4][10] - Zhongcheng Consulting has an issuance price of 14.27 CNY per share and a P/E ratio of 9.69, compared to the industry average of 40.16 [10] Group 2: Fengbei Biological - Fengbei Biological is a leading company in the comprehensive utilization of waste oil resources, focusing on a production chain from waste oil to biofuels and biobased materials [3][4] - The company reported revenues of 1.709 billion CNY in 2022, with a slight increase to 1.728 billion CNY in 2023, and projected revenues of 1.948 billion CNY for 2024 [5] - For the first half of 2025, Fengbei Biological expects revenues between 2.1 billion CNY and 2.3 billion CNY, representing a year-on-year growth of 51.40% to 65.82% [8] Group 3: Zhongcheng Consulting - Zhongcheng Consulting is an early player in the engineering consulting sector, providing comprehensive consulting services including cost estimation and project management [11] - The company has a significant reliance on clients within Jiangsu Province, with over 96% of its revenue coming from this region from 2022 to 2025 [11] - Revenue figures for Zhongcheng Consulting show a growth from 303 million CNY in 2022 to 368 million CNY in 2023, with a projected revenue of 396 million CNY for 2024 [11] Group 4: Delijia - Delijia is a leading company in the wind power industry, specializing in the research, production, and sales of precision gear transmission products [18] - The company reported revenues of 3.108 billion CNY in 2022, with a decline to 4.442 billion CNY in 2023, and a projected revenue of 3.715 billion CNY for 2024 [18] - For the first half of 2025, Delijia expects revenues between 3.938 billion CNY and 4.073 billion CNY, indicating a year-on-year growth of 61.39% to 66.92% [20]